Comparative Study of IGFBP Properties in Toad and Rat Sera by Cortizo, Ana María et al.
GENERAL AND COMPARATIVE ENDOCRINOLOGY 92, 242-249 (1993) 
Comparative Study of IGFBP Properties in Toad and Rat Sera 
A. M. CoRT1zo,•·1 D. BRAZIUNAS,* H. JASPER,t.2 AND J. J. GAGLIARD1No*·2 
*CF:NE,J(A, Centro de Endocrinologfa Experintental y Aplicada (UNLP-CONlCEn, 60 y 120 (1900) La 
Plata, Ar,;entina: and tCElJIE, Centro de ln\•esrigaciones E11docri11ol6gicaJ, Dil'isi611 de Endocrinolog{a, 
l/oJpital General de Niiio.~ "Ricardo GutiCrrez," Gallo 1330 (1400) Buenos Aires, Argentina 
Accepted July 14, 1993 
The levels of IGF-1 have been simultaneously measured by radioimmunoassay in samples 
of the toad Bttfo arenanun and of normal male Wistar rats. In addition, the different frac-
tions of IGF-1 binding proteins (IGFBP) and their binding properties have been identified by 
lignnd blot and Scatchard analysis in the serum of both species. In the toad, we have 
measured levels of IGF-1 (2.78 ± 0.48 ng/ml) similar lo those previously reported in am-
phibians but far below those found in rats. IGFBP levels \Vere estimated at 129 ::!:: 23 and 
4249 ± 321 pg/ml in toad and rat serum samples. Two main IGFBP fractions of 30-34 kDa, 
acco1npanied by a n1inor component of 24 kDa and seldom by another of 40 kDa, were 
identified in toad serum. In rat serum-as already reported-three bands of 40, 30, and 24 
kDa were identified, the first being the main component and the last the minor one. The 
Scatchard analysis of a competitive binding assay showed two types of binding sites in toad 
serum: one of high affinity-low capacity (Ka 1 "" I .6 x 10io M- 1 ; R 1 = I .2 x 10- 11 M) and 
another with low affinity-high capacity (Ka2 = 1.9 X 108 M- 1; R2 = 1.9 x 10- 10 M). The 
percentage fraction of these binding sites occupied by lGF-l was 13.5%. The figures for K1 
and K2 were lower and those for R 1 and R 2 were higher in rat than in load serum. The 
percentage fraction of occupied rat lOF binding sites was 3.6%. The lGF carrier levels 
(IGFBP,.) estin1ated in our laboratory in samples of rat and toad serum gave figures that were 
almost 33 times lower in the latter than in the former. Hence, the fraction of free and bound 
IUF-1 in toad and rat blood might be different. Our results provide new evidence of 
the presence and the properties of IGFBP in an1phibians, confirming the wide distribution of 
this carrier among different species and its possible role as modulator of IGF-1 biological 
effects. C 1993 Academic Press, Inc. 
Insulin-like growth factor l (10 F-1), a 
well-known growth-promoting agent (Van 
Wyk, 1984), mediates the action of the 
growth hormone in several target tissues 
through initial interaction with specific 
Type 1-IGF cellular receptors (Flier et al., 
1986). The endocrine pancreas would be 
among such IGF-1 target tissues (Swenne et 
al., 1989). 
In i-il'o, IGF-1 circulates in plasma in as-
sociation with specific high-affinity binding 
proteins (IGFBPJ (Rechler and Nissley, 
1990). These IGFBP do not act as merely 
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passive transporters or the hormone, but 
rather modulate lGF-1 action by altering its 
interaction with !hose specific cellular re-
ceptors (Rutanen, 1990; Yaleman et al., 
1993). It has also been suggested that the 
IGFBP could alter not only the effective 
concentration of IGF available for binding 
to its receptors but also the number of po-
tential IGF-l binding sites on the plasma 
membrane of the target cell (McCusker et 
al., 1991). 
Since many years ago, our group has 
been involved in the study of endocrine 
pancreas function and its growth control. 
Consequently, we have been looking for 
suitable models for studying such processes 
both in vivo and in vitro. We have recently 
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found that the pancreas of the toad (Bufo 
arenarum) has some properties-such as an 
active cellular growth and duplication in the 
adult-that could become a useful in vivo 
model for our studies. Hence, we would 
like to characterize in this model the rela-
tionship between the IGF-IGFBP system 
and the growth of the endocrine cells in the 
pancreas. For this purpose we have cur-
rently studied the levels of IGF-1 and 
IGFBP in the serum of the toad Bufo are-
narum and compared them with those mea-
sured in normal rats. We have also at-
tempted to identify the different serum 
IGFBP fractions and their binding proper-
ties in both species. 
MATERIALS AND METHODS 
Materials. Rabbit polyc\onal IGF-1 antibody (UBK 
487) was kindly provided by Dr. L. E. Underwood 
(Division of Pediatric Endocrinology, University of 
North Carolina, Chapel Hill, NC); recombinant human 
IGF-1 (hIGF-1) was purchased from Bachem Inc. (Tor-
rance, CA); 1251 was obtained from New England Nu-
clear (Boston, MA); 123I-IGFBP3 was kindly provided 
by Dr. Verghese from Diagnostic Systems Laborato-
ries Inc. (Webster, TX); glucose GOD-PAP kit for glu-
cose determination was kindly provided by Boehringer 
Mannheim Argentina (Buenos Aires, Argentina); hu-
man immunoglobulin was kindly provided by Gador 
(Buenos Aires, Argentina); fatty-acid-free bovine se-
rum albumin, X-Omat Kodak Film, prestained molec-
ular weight marker proteins and other reagents of the 
purest available grade were obtained from Sigma 
Chemical Co. (St. Louis, MO). 
Male adult specimens of Bufo arenarum Hensel 
toads of about 130 g body weight, captured during our 
autumn season in La Plata (Argentina) were used in 
this study. The animals were maintained in a suitable 
enclosure containing water and insects. Their diet was 
supplemented with mealworms. To petform various 
experiments, the toads were pithed by severing the 
spinal cord and blood samples (2-3 ml) were later ob-
tained by cardiac puncture. 
Normal male Wistar rats of about 250 g body weight 
were used as blood donors. These animals had free 
access to tap water and standard commercial chow 
diet. Blood samples (3 ml) were obtained from the ret-
roorbital plexus under light ether anesthesia. 
After being allowed to clot, blood samples were cen-
trifuged (lOOOg for 15 min) at 4° and stored at -20° for 
no longer than I week until the petformance of differ-
ent assay procedures. 
Serum glucose and protein levels were determined 
by the glucose oxidase and Bradford's (1976) methods, 
respectively. 
Total serum IGF-1 was measured in single samples 
by radioimmunoassay (Furlanetto et al., 1977) after 
extraction of the IGFBP with a mixture of formic 
acid-Tween 20-acetone (Bowsher et al., 1991). 
Each sample was measured in triplicates; recovery ex-
periments petfonned with this procedure show a I 00% 
value. For the assay procedure the UBK 487 IGF-1 
polyclonal antibody (diluted 1: 18,000) was used and 
hlGF-1 was employed for standards and tracer. hlGF-l 
was iodinated with a specific activity of 400-450 µCi/ 
mg using the chloramine T procedure (D'Ercole et al., 
1976). RIA data were analyzed using the RIA Data 
Reduction Program for the IBM-PC (Rodbard, 1984). 
The intra- and interassay coefficients of variation were 
10.9 and 13.0o/o, respectively. 
Although Pancak-Roesler and Lee (1990) using the 
same IGF-1 antibody as we did demonstrated that after 
acid-ethanol treatment toad plasma and purified 
hIGF-1 standards gave parallel displacement curves, 
we repeated such cross-reactivity study under our as-
say conditions. Figure I shows that in the range of 20 
to 50 pg/tube of our standard curve, appropriate dilu-
tion of toad serum samples and the hlGF-1 standards 
produced a parallel displacement of the tracer. Conse-
quently, and for assay purposes, toad serum samples 
were carefully diluted in order to read all of them 
within such concentration range. 
IGFBP were studied using the ligand blotting tech-
nique described by Hossenlopp et al. (1986). For that 
purpose, 30 µI of serum samples were mixed with a 
four-times concentrated sample buffer (62.5 mM Tris-
HCl. pH 6.8, 2% SDS, 10% (vlv) glycerol and 0.001% 
bromophenol blue) (Laemmli, 1970) under nonreduc-
ing conditions and boiled for 3 min before being loaded 
onto a 12.5% SDS-polyacrylamide gel. Samples were 
electrophoresed at 200 V until the dye front reached 
the bottom of the gel. Prestained molecular weight 
100 
.... 
l':_, 
--··~, ·-.-~ --... ... 
.. 
til • 
• '10 
• 
''•-_ 
"' 
IGl'-1 ~.t.J<Hfo<•J 
"' .. Toad snum • 
?' •• J 
0 -------------- ---- ---·--------- f --
1 (J 100 r ~'Y I lub<; J 
F1G. I. Displacement curves showing parallelism 
between hIGF-1 and different volumes (6, 8, and 10 µI) 
of toad serum. (e) hlGF-1; and (A.) toad plasma. 
244 CORTIZO ET AL. 
marker proteins were run in a parallel lane. Proteins 
were transferred to nitrocellulose membranes at room 
temperature in a 15 mM Tris base-120 mM glycine 
buffer, pH 8.3, containing 5% (v/v) methanol. Elec-
troblotting was performed under a constant current at 
100 mA for 16-18 hr. After the gels had been trans-
ferred, they were stained to detect any untransferred 
proteins. The nitrocellulose paper was blocked at 4° as 
described by Hossenlopp et al. (1986) and incubated 
with 1251-hIGF-l (2 x 105 cpm/ml) in 1 % fatty-acid-free 
bovine serum albumin -0.1% Tween 20 in TS (trans-
fer-saline) buffer (150 mM NaCl, 10 mM Tris-HCl, pH 
7.4, 0.5 mg/ml sodium azide). The specificity of 1251-
hIGF-I binding to each IGFBP was assessed by com-
plete displacement of the tracer by the addition of 2.5 
µM cold hIGF-1 to the incubation medium (data not 
shown). Following this incubation, the membranes 
were washed and autoradiographed using X-On1at 
Kodak film and a Dupont intensifying screen, for ap-
proximately 3 days. To measure the amount of labeled 
IGF bound to each IGFBP fraction, the nitrocellulose 
paper was cut into strips and counted as described by 
Cortizo and Gagliardino (1991). Based on the known 
specific activity of the 1251-hlGF-I tracer employed we 
estimated the levels of IGBP assuming a 1:1 relation-
ship between both reactants. 
The 1251-hIGF-I binding capacity and the affinity 
constant of the serum were measured by Scatchard 
analysis. For this purpose, 20 µI of toad serum and 10 
µI of rat serum were incubated for 2 hr at 22° in the 
presence of 1251-hIGF-I (20,000 cpm/tube), either with 
or without the addition of increasing amounts of unla-
beled hIGF-1 in a total volume of 250 µI assay buffer 
(McCusker et al., 1991). At the end of the incubation 
period, 250 µI of0.2% human immunoglobulin, diluted 
in the assay buffer, and 0.5 ml of 25% PEG-8000, di-
luted in water, were added. The mixture was incu-
bated for 10 min at 4° and centrifuged (3 min at 8000g); 
the supernatant was removed and the pellet was 
washed in 6.25% PEG-8000 and centrifuged as before. 
The radioactivity associated with the pellet was mea-
sured by determining the counts per minute of 1251-
hIGF-I in a well gamma counter. Nonspecific binding 
was considered as the amount of labeled peptide pre-
cipitated in the absence of added IGFBP. The data 
were analyzed by nonlinear least-squares curves fit-
ting using the LIGAND program (Munson, 1987). 
RESULTS 
Serum glucose and protein levels mea-
sured in toads were 1.8 ± 0.1 mM and 45 ± 
3 mg/ml (n = 23) respectively. In the rat 
these values were 6.3 ± 0.6 mM for glucose 
levels and 99 ± IO mg/ml (n = 15) for pro-
tein concentration in serum. 
The IGF-I levels in toad serum showed 
high individual variability ranging from 1. 1 
to 7.8 ng/ml with an average of 2.8 ± 0.5 
ng/ml (n = 23). These levels were two or-
ders of magnitude lower than those mea-
sured in rat serum (Table 1). 
To determine the presence of IGFBP in 
toad and rat serum, different volumes of 
serum samples were incubated with a con-
stant amount of 125I-hIGF-I (6.5 x 10- 11 
M), with and without the addition of 10-7 
M hIGF-1. Figure 2 shows that toad and rat 
sera bound 125I-hIGF-I in a specific man-
ner; smaller volumes of rat than of toad se-
rum were necessary to reach plateau-
percentage SB/T values (10 vs 25 µ.!), this 
value being higher for the former (-22%) 
than for the latter (-11%). 
Figure 3 shows displacement curves ob-
tained by incubating a constant volume of 
toad (a) and rat (b) serum and of 125!-h!GF-I 
together with increasing amounts of cold 
h!GF-1. In those curves the EC50 values 
were 0.45 and 1.0 nM for toad and rat se-
rum, respectively. 
The Scatchard analysis of such data 
showed two types of binding sites in both 
species of serum: one of high affinity-low 
capacity and another with low affinity-high 
TABLE I 
COMPARATIVE IGF-1 LEVELS AND IGFBP 
PROPERTIES OF TOAD AND RAT SERUM SAMPLES 
Parameter Toad 
Serum IGF-1 levels 
(M) 3.6 x 10- 10 (23) 
Serum IGF-1 levels 
(pg/ml) 129 ± 23 (16) 
K,.1 (M-1) 
R1 (M) 
Ka2 (M- 1) 
R, (M) 
y(%) 
Scatchard analysis data 
1.6 x 1010 
1.2 x 10- 11 
1.9 x 108 
1.9 x 10- 10 
13.5 
R" 
8.0 x 10-s (15) 
4249 ± 321 (14) 
3.9 x 109 
8.5 x 10- 11 
1.5 x 107 
8.8 x 10- 9 
3.6 
Note. Serum IGF-1 levels are expressed in M concentration 
for the sake of comparison with the Scatchard analysis data. 
Each value represents the average ±SEM. The number of 
cases is between parentheses. All of the determinations were 
performed by triplicates in at least two different assays. y (%) 
represents the percentage of IGFBP binding site occupation 
(fractiona1 occupancy) and was obtained using the equation y 
= BIR0 x 100 (Cuatrecasas et al. 1976). 
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FIG. 2. Specific binding of 1251-hlGF-l to different 
volumes of toad and rat serum. This value was ob-
tained by subtracting at each volume tested the one 
obtained with the same volume in the presence of 10-1 
M unlabeled hlGF-L Each point represents the mean 
::t SEM of two separate experiments performed in trip-
licate. 
capacity (Figs. 3c and 3d). The correspond-
ing values for these parameters are listed in 
Table I. Toad serum showed a higher ap-
parent affinity at both binding sites (K 1 and 
K2 ) than rat serum did while the number of 
binding sites were lower in the former than 
in the latter. The values in Table 1 also 
show that the percentage fraction of these 
binding sites occupied by !GF-1 is larger in 
toad than in rat serum. 
To further characterize the IGFBP, se-
rum samples of toads and rats were submit-
ted to ligand blot analysis. As it is shown in 
Fig. 4, in the toad serum two main bands 
with M, of 30-34 kDa were observed, with 
similar M, to the IGFBP-1 and IGFBP-2 
found in the rat and the IGFBP-2 in the fetal 
calf serum. A thin band of 24 kDa and oc-
casionally a diffuse band of M, 40 kDa were 
also detected; the 24-kDa band was similar 
to the lGFBP-4 detected using the same 
procedure in rat serum. Thus, according to 
the ligand blot analysis, an IGFBP with ap-
parent M, 30-34 kDa appears as the main 
carrier for the lGF-1 in toad serum. 
Three bands with molecular weights of 40 
(IGFBP-3), 30, and 24 kDa were identified 
in rat serum (Fig. 4), the first being the main 
component and the last the minor one. 
DISCUSSION 
Immunoassayable levels of lGF-1 were 
detected in individual toad serum samples 
in a range between I.I and 7.8 ng/ml. Wider 
variations were reported by other authors 
who have measured IGF-I in pooled serum 
of various anuran species (Daughaday et 
a/., 1985; Pancak-Roesler and Lee, 1990); 
furthermore it has been reported that serum 
lGF-1 levels in toad undergo circannual 
variations (Pancak-Roesler and Lee, 1990). 
Plasma protein also has circannual varia-
tions but with an otherwise uneven distri-
bution of peak and trough values (Robert-
son, 1986). Therefore, each rhythm might 
be under the control of a different synchro-
nizer. Such variations do not explain the 
fluctuations we are reporting since all the 
blood sampling was performed at one sea-
son. Hence, our differences might repre-
sent individual variations of the serum hor-
mone levels. 
Using the same lGF-1 antibody as we do, 
Pancak-Roesler and Lee (1990) have shown 
that after acid-ethanol treatment, toad and 
human plasma and purified human !GF-1 
standards gave parallel displacement 
curves. The 81% homology of the amino 
acid sequence of the primary lGF-1 trans-
lation product of amphibian (Xenopus lae-
vis) with the one corresponding to hlGF-1 
might support those results, (Kajimoto and 
Rotwein, 1990). Although this parallelism-
which we have confirmed-and the above 
mentioned hormone-molecular homology 
grant validity to the comparison of relative 
IGF-1 serum levels, there is no certainty 
regarding the real absolute values since the 
standard employed in the immunoassays 
was hIGF-1. To avoid this problem, other 
authors have expressed the hormone values 
as nanograms of equivalents of h!GF-1 
(Daughaday et al., 1985; Pancak-Roesler 
and Lee, 1990). Despite this fact, it seems 
to be that lGF-1 levels measured in toads 
are 50 to 200 times lower than those re-
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FIG. 3. Displacement of 125I~h1GF-1 binding to 20 µ.l of toad serum (a) and 10 µ.I of rat serum {b) by 
different concentrations of unlabeled IGF-1. Specific binding represents the value obtained by sub-
tracting at each hormone concentration the value obtained in the presence of 10- 7 unlabeled hlGF-1 
and expressed as a percentage of the total count. Scatchard analysis of the data represented in a and 
b are plotted in c (load) and d (rat). 
ported in human (Ranke et al., 1988) and rat 
(Yang et al., 1989) serum. In this regard, it 
must be considered that other components 
of the toad serum such as glucose and pro-
tein levels measured by ourselves and by 
other authors are also significantly lower 
than those found in mammals (Robertson, 
1986; Miller, 1960). These data would sug-
gest that, in amphibians, the hormone-
metabolic homeostasis set point is set at a 
lower value than in mammals. 
The presence of IGFBP in toads was ini-
tially reported by Daughaday et al. (1985) 
using 125!-IGF-II as a tracer and gel filtra-
tion for its determination. According to 
these authors, the bound tracer to the se-
rum protein fractions was not displaced by 
added unlabeled IGF-ll and consequently 
was considered nonspecific. Pancak-
Roesler and Lee (1990) later reported that 
most of IGF immunoreactivity in anuran 
plasma was associated with an acid-
dissociable high-molecular-weight fraction. 
Using size exclusion chromatography for 
its separation from the other serum proteins 
and labeled recombinant h!GF-I for its 
identification, they conclude that the 
IGFBP might have a molecular weight of 
-50 to 60 kDa. Our results confirm the 
presence of IGFBP in the toad serum, how-
ever, and probably due to the different 
methodology employed-ligand blot in-
stead of size exclusion chromatography-
our results do not fully agree with those 
previously reported. Using 125!-hIGF-I in a 
Western ligand blot procedure Kelly and 
Siharat would have obtained. comparable 
results to our own in the plasma of the bull-
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FJG. 4. Ligand blot of toad serum. Thirty microli-
ters of toad serum was electrophoresed through a 
12.5% nonreduced SDS-PAGE, electroblotted to ni-
trocellulose paper, and incubated with ml-hIGF-I. 
The M. of each IGFBP was estimated by comparison 
to prestained molecular weight marker proteins. Each 
lane represents: (I) 5 µI of rat serum, (2) 2 µI of human 
serum, (3) 5 µI of human serum, (3 and 4), 30 µI of toad 
serum, and (5) 5 µI of fetal calf serum. 
frog: binding bands between 25 and 50 kDa 
(data quoted in the paper of Bern et al., 
1991). 
In toad serum we have identified IGFBP 
fractions with Mr similar to the ones re-
ported in mammals (Yang et al., 1989) but 
with an otherwise different distribution. In 
fact , two bands with 30--34 kDa appeared as 
the main serum IGF carrier together with a 
light fraction of 24 kDa. Occasionally, a 
third diffuse band of 40 kDa was also de-
tected. This IGFBP pattern contrasts with 
the one corresponding to rat-and also with 
human-serum, where the 40-kDa fraction 
represents the main component. Negative 
results were obtained when IGFBP-3 pro-
teolysis was studied in toad serum using 
1251-IGFBP-3 as described by Lamson et al. 
(1991) (data not shown). Hence, the infre-
quent appearance of such low IGFBP-3 lev-
els found in toad serum might be genuine 
and characteristic of this species rather 
than the consequence of self-degradation 
during handling procedures. 
The displacement curves performed us-
ing whole serum samples, labeled and un-
labeled hIGF-1, demonstrate the specificity 
of the binding of the toad serum IGFBP as 
well as its properties. The latter were com-
parable to those we have simultaneously 
measured in the rat serum, being the first 
experimental evidence reported on this 
matter. 
A rough estimate of the IGF carrier lev-
els (IGFBPs) measured in our laboratory in 
samples of rat and toad serum indicates that 
in the latter, the figures were almost 33 
times lower than those in the former. The 
values for binding capacity measured in the 
sera of these species were also higher in 
rats than in toads. Thus, with the concerns 
already mentioned regarding absolute se-
rum levels of IGF in the toad, these levels 
together with the differences recorded in 
the number of IGF-1 binding sites, their af-
finity constants and their percentage of oc-
cupancy might indicate an uneven relation-
ship between the fraction of free and bound 
IGF-1 in the serum of toads and rats as pre-
viously suggested by Daughaday et al. 
(1985). According to these authors this fact 
might explain the relatively greater biolog-
ical activity of nonmammalian serum in bio-
assays than in receptor and immunoassays 
(Shapiro and Pimstone, 1977; Wilson and 
Hintz, 1982). This assertion remains to be 
confirmed as well as its possible physiolog-
ical significance. 
Altogether our data provides new evi-
dence of the presence and the properties of 
IGFBP in amphibians , confirming its wide 
distribution among different species and its 
possible role as modulators of the IGF-1 bi-
ological effects. 
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